Member Exclusive

ISCT revises cell and gene therapy forecast following FDA approval of Novartis CAR-T therapy

Following FDA approval of the Novartis CAR-T cell therapy CTL019, ISCT forecasts significant investment and funding throughout entire cell and gene therapy sector.

Go to the profile of Freya Leask
Aug 31, 2017
3
0

Please sign in or register for FREE

Register to RegMedNet

RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.

Register

No comments yet.